

1 **Atlantic salmon post-smolts adapted for a longer time to seawater develop an effective**
2 **humoral and cellular immune response against Salmonid alphavirus**

3

4 Noelia Nuñez-Ortiz¹, L. J. Moore^{1,2}, J. Jarungsriapisit^{1,3}, T. O. Nilsen⁴, S. Stefansson⁵, H. C.
5 Morton¹, G. L. Taranger¹, C. J. Secombes⁶, and S. Patel^{1,7*}

6

7 ¹ Institute of Marine Research, P.O. Box 1870, Nordnes, 5817 Bergen, Norway

8 ² Present address: Department of Biological Sciences, University of Bergen, Norway

9 ³ Present address: Aquatic Animal Health Research and Development Division, Department of
10 Fisheries, Pahonyothin Ladyow Jatujak, 10900 Bangkok, Thailand

11 ⁴ Uni Research Environment, Uni Research, NORCE, Nygårdsgaten 112, 5006 Bergen,
12 Norway

13 ⁵ Department of Biological sciences, University of Bergen, P.O. Box 7803, 5020 Bergen,
14 Norway

15 ⁶Scottish Fish Immunology Research Centre, University of Aberdeen, Zoology Building,
16 Tillydrone Avenue, Aberdeen AB24 2TZ, Scotland, UK

17 ⁷ Present address: Vaxxinova Norway, Kong Christian Frederiks plass 3, 5006 Bergen, Norway

18 *Corresponding author

19

20

21

22

23 ABSTRACT

24 Salmonid alphavirus (SAV) causes pancreas disease (PD) in Atlantic salmon (*Salmo salar* L.)
25 and disease outbreaks are mainly detected after seawater transfer. The influence of the
26 smoltification process on the immune responses, specifically the adaptive response of Atlantic
27 salmon after SAV infection, is not fully understood. In this study, Atlantic salmon post-smolts
28 were infected by either bath immersion (BI) or intramuscular injection (IM) with SAV subtype
29 3, 2 weeks (Phase A) or 9 weeks (Phase B) after seawater transfer. The transcript levels of
30 genes related to cellular, humoral and inflammatory responses were evaluated on head kidney
31 samples collected at 3, 7, 14, 21, and 28 days post-infection (dpi). Corresponding negative
32 control groups (CT) were established accordingly. Significant differences were found between
33 both phases and between the IM and BI groups. The anti-inflammatory cytokine IL-10 was up-
34 regulated in Phase A at a higher level than in Phase B. High mRNA levels of the genes RIG-1,
35 SOCS1 and STAT1 were observed in all groups except the BI-B group (BI-Phase B).
36 Moreover, the IM-B group showed a higher regulation of genes related to cellular responses,
37 such as CD40, MHCII, and IL-15, that indicated the activation of a strong cell-mediated
38 immune response. CD40 mRNA levels were elevated one week earlier in the BI-B group than
39 in the BI-A group (BI-Phase A). A significant up-regulation of IgM and IgT genes was seen in
40 both IM groups, but the presence of neutralizing antibodies to SAV was detected only in Phase
41 B fish at 21 and 28 dpi. In addition, we found differences in the basal levels of some of the
42 analysed genes between non-infected control groups of both phases. Findings suggest that
43 Atlantic salmon post-smolts adapted for a longer time to seawater before they come into contact
44 with SAV, developed a stronger humoral and cell-mediated immune response during a SAV
45 infection.

46

47 Keywords: *Salmo salar*, bath immersion, adaptive response, smoltification,, Immunoglobulin,
48 B cells, RIG-1, SOCS1, CD40, Interleukin.

49

50 **1. Introduction**

51 Pancreas disease (PD) is a systemic disease characterized by inflammation and cellular necrosis
52 in exocrine pancreas and subsequent severe cardiac and skeletal myopathies, which results in
53 high morbidity and mortality of farmed Atlantic salmon (*Salmo salar*) [1]. Salmonid alphavirus
54 (SAV), a single-stranded, positive-sense RNA virus of the family *Togaviridae*, is the
55 aetiological agent of PD. Six geographically distributed subtypes of SAV have been described
56 on the basis of partial sequences of the E2 and nsP3 genes [2]. PD has been described in
57 Atlantic salmon farms in Scotland, Norway, Ireland, France, Spain, and North America [3]. PD
58 outbreaks in south-western Norway are mainly associated with Salmonid alphavirus subtype 3
59 (SAV3), which can be spread horizontally between neighboring salmon farms [4,5].

60 Atlantic salmon aquaculture is normally carried out in two phases: firstly, in land-based
61 hatcheries where smolts are produced in freshwater tanks using flow-through and re-circulation
62 systems; and later in an on-growing phase in seawater cages until harvest [6]. It is during the
63 seawater phase that the farmed Atlantic salmon are most vulnerable to infection from diseases
64 and parasites partly due to less possibility of controlling the culture conditions. For instance,
65 natural outbreaks of PD in Atlantic salmon have only been reported in the seawater phase [7]
66 and therefore PD outbreaks and higher losses are reported in the months after seawater transfer
67 (SWT). It is known that smoltification and the initial period following seawater transfer is a
68 time of high energy requirement due to the necessary physiological changes to adapt to
69 seawater. The smoltification process (also known as Parr-Smolt transformation) is a series of
70 physiological, morphological and behavioral changes [8,9]. Moreover, immune suppression
71 characterized by a decrease of total white blood cells and circulating lymphocytes, a decrease

72 of plasma lysozyme activity, total serum immunoglobulin (Ig) M and total serum protein, and
73 a down-regulation of some immune genes has been described during smoltification [9-12].
74 These data suggest that Atlantic salmon in the process of smoltification and in the post-smolt
75 period may be especially vulnerable to infectious diseases. A link between smoltification and
76 susceptibility to Infectious Salmon Anemia Virus (ISAV) was proposed by Glover et al., 2006
77 [13]. Despite the use of vaccines, the PD challenges in salmon farms persist, but few studies
78 have evaluated immune responses of Atlantic salmon to PD a few weeks after seawater transfer.
79 Previous studies employing injection or cohabitation challenge models have demonstrated a
80 high level of expression of IFN- γ , two IFN- γ responsive genes, and TCR- β genes, suggesting
81 a sustained acquired immune response in the skeletal muscle [14]. Moreover, a rapid activation
82 of MHC I and II responses during the early stages of SAV subtype 1 infection have been
83 reported [15]. Enhanced expression of T cell-related genes such as, T cell co-receptors CD4-1
84 and CD8 α , and TCR- β , as well as MHCII, normally expressed only on antigen-presenting cells,
85 have been detected during the later stages of SAV3 infection [16,17,14].

86 We have established a bath challenge model based on the viral shedding capacity of Atlantic
87 salmon experimentally injected with SAV. When used in a bath challenge of naïve fish this
88 SAV3 containing water mimics the natural exposure to water-borne virus. Compared to
89 cohabitation challenge, a bath challenge model has the advantage of limiting the infection time
90 to a small window which is useful when studying the time frame of the subsequent immune
91 responses. The susceptibility of Atlantic salmon post-smolts at 2 and 9 weeks post seawater
92 transfer (wpt) to SAV3 by comparing fish infected via the bath challenge (BI) model and by
93 intramuscular (*i.m.*) injection (IM) has been reported [18]. In addition, we have studied the
94 immune-related gene regulation of some antiviral immune genes and genes involved in the
95 pathways leading to interferon (IFN) regulation and the production of ISGs. Smolts fully
96 acclimatized to seawater showed an increased innate immune response to SAV infection and a

97 higher basal abundance of several innate immune genes relative to the smolts that were infected
98 shortly after seawater transfer [19].

99 In the present work, we have focused on analysing transcript levels of genes directly or
100 indirectly involved in adaptive responses, including genes that express cell surface
101 receptors/markers, in Atlantic salmon post-smolts transferred to seawater seven weeks apart
102 and then infected with SAV3 by BI or IM. The obtained data will give a more comprehensive
103 understanding of the factors determining survival of salmon suffering from pancreas disease
104 after seawater transfer and the associated immunological events.

105

106 **2. Materials and Methods**

107 **2.1 Experimental design, tissue collection, and RNA extraction**

108 Atlantic salmon post-smolts from the same batch of fish (Aquagen strain) were challenged with
109 SAV3 either 2 (Phase A, average weight of 41 g) or 9 (Phase B, average weight of 89 g) weeks
110 after seawater transfer (oxygen saturation of >85 %; 12 °C; salinity 34.5‰). Na⁺, K⁺-ATPase
111 (NKA) enzyme activity was evaluated in the gills of fish from Phase A and acceptable NKA
112 activity was observed, and thus this was deemed to have no influence on SAV infection [18].
113 NKA levels were not evaluated in fish from Phase B because both groups belonged to the same
114 production batch and after 9 weeks, the fish appeared well adapted to seawater.

115 The experimental setup consisted of three groups: negative control (CT); intramuscular
116 injection (IM); or bath immersion (BI) and each of these groups were in triplicate tanks with
117 65 fish per tank (Fig. 1A). Fish in the IM group were infected with 10⁴ TCID₅₀ SAV3
118 propagated in Chum salmon heart-1 (CHH-1) cells [20] and quantified by end-point dilution
119 assay (TCID₅₀) [21]. Fish in the BI group were bath immersed for 6 h in seawater containing
120 SAV3, which was shed by shedder fish injected with 10⁴ TCID₅₀ SAV3/fish one week before
121 the experiment started. The bath immersion dose was estimated by a one-step RT-qPCR assay

122 of filtered/concentrated shedder tank water, which resulted in an average Ct value of 28 and 34
123 in Phases A and B, respectively [18]. Infected groups from Phase A were named IM-A and BI-
124 A, and infected groups from Phase B were named IM-B and BI-B. Fish belonging to the control
125 group from Phase A (CT-A) and from Phase B (CT-B) were injected with supernatant of non-
126 infected cultures of CHH-1 cells. The SAV3 isolate prepared for use in this experiment was
127 later found to be contaminated with low levels of infectious pancreatic necrosis virus (IPNV).
128 However, compared with the SAV3, the level of IPNV was so low that it is unlikely to have
129 caused any discernable effect on the interpretation on the immune gene regulation evaluated
130 post-infection. In fact, anterior kidney samples from the BI-A group were IPNV negative, and
131 only 6 fish in the IM-A group and 4 fish in the IM-B group were IPNV positive, with very low
132 virus loads (Cts all >36) [22]. Before handling, the fish were bath anaesthetized with a mixture
133 of Metomidate (10 mg L⁻¹) and Benzocaine (60 mg L⁻¹), and before sampling, fish were killed
134 employing Metomidate and a higher dose of Benzocaine (160 mg L⁻¹). The animal care and
135 experimental setup were performed in accordance with the established guidelines and approved
136 by the Norwegian Animal Research Authority (ID: 5651). Further information on experimental
137 procedures, fish, and virus have been published previously [18].

138

139 Total RNA from head kidney tissue samples described in this study were previously used to
140 study innate immune gene responses [23,19]. Briefly, head kidney tissue samples were
141 collected from fish in each treatment group and frozen in liquid nitrogen at 3, 7, 14, 21, and 28
142 days post-infection (dpi). Total RNA was extracted using an iPrep™ PureLink® Total RNA
143 Kit (Invitrogen, USA.) with TRIzol® reagent (Ambion) and following the manufacturer's
144 instructions. RNA concentration was measured using a Nanodrop ND-1000. Five percent of
145 the RNA samples from tissues were randomly chosen and checked for integrity on a
146 Bioanalyser (Agilent Instruments), resulting in RINs of ≥ 9 for all samples tested.

147

148 **2.2 cDNA synthesis and quantitative PCR (RT-qPCR)**

149 qScript™ SuperMix (Quanta Biosciences) was used to transcribe cDNA from 1 µg head kidney
150 total RNA in a 20 µl reaction including priming with both random hexamers and Oligo-dT as
151 described in the manufacturer's instructions. The cDNA was diluted 1:10 with AMRESCO's
152 sterile, Nuclease-free water (VWR) as this was previously demonstrated to be an optimal
153 dilution for the analysis performed in this study. Assays for CD40, IgM and IgT, SOCS1, CD4-
154 1, CD8α, Retinoic-acid-inducible protein 1 (RIG-1), Nuclear factor kappa-light-chain-
155 enhancer of activated B cells (NFκB), four Interleukins (IL), and the IL-2 Receptor β chain
156 protein (IL2Rβ) were designed for use in this study. Target-specific RT-qPCR primers were
157 designed to either span exon-exon boundaries, or to have at least one primer spanning an exon
158 boundary of the gene of interest. All assay products were visualized on a 3% MetaPhor®
159 Agarose gel (Lonza) and sequenced to verify the specificity of the assay. Assays for Signal
160 transducer and activator of transcription 1 (STAT1), MHCIIβ, and Elongation factor 1A
161 (EF1A) were adapted from previously published studies [24-26]. Efficiency was calculated for
162 each primer set using triplicates of a five-point, 4 x dilution series of pooled cDNA. EF1A was
163 used for normalization and is considered the best option of several endogenous reference genes
164 evaluated for use with Atlantic salmon during SAV infection [27]. All primers and efficiency
165 data for the assays used in this study are listed in Table 1.

166 RT-qPCR was run in 384 well plates using Brilliant III Ultra-Fast SYBR® Green master mix
167 (Agilent) and Applied Biosystems 7900HT Fast Real-Time PCR system in a 7 µL reaction
168 volume containing 2 µL diluted cDNA and 400 nM of each primer. The running conditions
169 were as recommended by the manufacturer and a melting curve analysis was included for each
170 run. The Ct values were normalized using the Ct values from the EF1A assay run on the same
171 plate for each individual (ΔC_t). Fold change ($2^{-\Delta\Delta C_t}$) of transcript level for each individual was

172 calculated by subtracting the relevant mean ΔC_t values obtained from 3 calibrator fish, sampled
173 before the start of the experiment (Day 0). Outliers were not removed from any of the data sets
174 for either analysis or presentation in the figures, as they represent the real biological diversity
175 within these groups.

176

177 **2.3 Neutralizing antibody titres to SAV**

178 Blood was collected by caudal vein puncture and plasma was obtained by centrifuging the
179 blood at 16000 g for 15 min at 4 °C the day of collection. Serum was allowed to clot overnight
180 and similarly separated the following day. All sera and plasma samples were stored at -80°C
181 until analysis. Eighteen plasma samples were randomly chosen from all groups in both Phase
182 A and B and eighteen serum samples were randomly chosen from all groups in Phase B at 21
183 and 28 dpi (with the exception that all individuals positive for SAV in the BI-B group were
184 included). Serum samples were only taken from Phase B fish. Neutralizing antibody titres to
185 SAV were measured by Agri-Food and Biosciences Institute (AFBI) in Belfast (UK) [28].

186

187 **2.4 Data Analysis**

188 The data from RT-qPCR were transformed (+1, \log_{10}) and the normal distribution was proved
189 by Levene's test employing the Statistica software package. Statistical analysis for
190 immunological parameters was performed by Graph Pad Prism 6.0 statistical software package.
191 The statistical significance between groups in Phase A and Phase B and between both phases
192 was determined using One-way ANOVA on log transformed data followed by Tukey's multiple
193 comparisons test. Results showing $p < 0.05$ are considered significantly different. Although
194 these methods use averages in their calculations, medians were used for discussion and visual
195 representation of the data, because of the asymmetric distribution of the data.

196 Average transcript levels of the genes analysed in positive and negative fish in both infected
197 groups and in the control group are also included (Supplementary figures S1 and S2). The
198 statistical significance between control fish and fish either positive or negative for SAV3 RNA
199 was estimated for each tested gene and also between all sampling time-points and also for both
200 phases when there was more than one positive or negative fish per sampling time-point (data
201 not shown).

202

203 **3. Results**

204 **3.1 SAV3 infection**

205 Two groups of Atlantic salmon post-smolts from the same batch, which were transferred to
206 seawater 7 weeks apart, were infected with SAV3 by IM or BI. The percentage prevalence at
207 each time point was determined by analysing the SAV3 RNA in heart tissue [18] (Fig. 1B).
208 Briefly, at the earliest sampling time-points the fish in the IM-A group had a higher prevalence
209 of SAV infection and higher viral loads than fish in the BI-A group. By 14 dpi the prevalence
210 in the IM-A and BI-A groups was 95.8% and 100%, respectively, but viral loads were still
211 lower in the BI-A group. At later time-points, all the BI-A fish were positive (100% prevalence)
212 and significantly higher amounts of SAV3 were detected. A maximum of 2 fish were negative
213 in the IM-A group at the last two sampling time-points.

214 In Phase B, 95% of the fish in the IM-B group were SAV3 positive at 7 dpi and they remained
215 almost 100% positive at all later time-points. The viral load in the IM-B group increased up to
216 14 dpi after which it decreased, falling to levels similar to those seen at 7 dpi levels by 28 dpi.
217 The BI-B group had only a few positive fish at 14 dpi and this remained the same until the end
218 of the experiment. At 21 dpi the SAV positive fish in the BI-B group also had relatively low
219 viral loads.

220

3.2 Transcript Profiles of Immune Response Genes

We have performed RT-qPCR on head kidney samples collected at 3, 7, 14, 21, and 28 dpi in order to study the effect of the extra time in seawater on transcript levels of immune genes related to cellular, humoral, and inflammatory responses. The reported changes in transcript levels are from median values calculated for the whole group that comprised 8 fish sampled from triplicate tanks (altogether 24 individuals per treatment at each sampling time-point). Many of the changes are heavily influenced by the infection status of the fish since not all fish exposed to SAV were SAV3- positive at all time-points. Specifically, infected fish in the BI-B group from Phase B were only found at 14, 21, and 28 dpi. Where these differences between positive and negative fish are significant, they are mentioned.

Inflammatory response

Transcript levels of IL-18, IL-10, RIG-1, SOCS1 and STAT1 genes, were also evaluated in this study to supplement our previous studies describing transcript abundance of other genes involved in the inflammatory response [23,19]. The mRNA level of pro-inflammatory fish cytokine IL-18 was down-regulated in all groups in Phase A compared to the calibrator fish taken before the experiment started. Conversely, in Phase B, IL-18 mRNA levels remained stable in most individuals throughout the experiment (Fig. 2). Interestingly, a significantly higher transcript abundance was detected at 7 dpi in SAV3-positive fish in the IM-B group. At 14 dpi some of the individuals from the IM-B group presented a 5- and 17-fold increase when the median value of the group was 1-fold.

IL-10, an anti-inflammatory cytokine and member of the class II cytokine family, was highly regulated at 7 and 14 dpi in the IM-A fish, reaching a peak at 7 dpi with 20-fold increases. IL-10 displayed a 5-fold up-regulation in the BI-A group at 14 dpi and it remained significantly elevated at 21 and 28 dpi. In contrast, IL-10 mRNA levels in fish from the IM-B group only

246 showed a 4-fold increase at 14 dpi in Phase B and was almost unchanged in the BI-B group at
247 all time-points (Fig. 2).

248 The viral RNA sensor, RIG-1, was highly up-regulated in Phase A. In the IM-A group, the
249 RIG-1 mRNA levels peaked with 17- and 14-fold increases at 7 and 14 dpi, respectively,
250 followed by a drop at 21 dpi. Fish in the BI-A group also showed significant up-regulation of
251 RIG-1 transcript levels already at 7 dpi, which peaked with significant 20- and 15-fold
252 increases at 14 and 21 dpi, respectively. The transcription pattern of RIG-1 was different in
253 Phase B, where the maximum regulation was seen at 14 dpi in both the IM-B and BI-B groups,
254 with moderate fold increases of 7.5 and 3, respectively. Furthermore, mRNA levels of RIG-1
255 had decreased by 28 dpi (Fig. 3).

256 Similar to RIG-1, the mRNA level of SOCS1 was higher in Phase A than in Phase B, with an
257 increase for both infected groups at 7, 14 and 21 dpi in Phase A (Fig. 3). In the IM-A group,
258 SOCS1 transcript levels peaked at 7 dpi but quickly decreased, while the BI-A group peaked
259 at 14 dpi to a level higher than the IM-A group at 21 dpi. Both returned to control levels at 28
260 dpi. Fish positive for SAV3 RNA in the IM-A and BI-A groups exhibited higher SOCS1
261 transcript levels than the negative fish at 7 dpi (S1). Similarly, in Phase B, positive fish showed
262 much higher mRNA levels of SOCS1 at 7 and 14 dpi in IM-B and at 14 and 21 dpi in BI-B
263 relative to the negative fish at the same time-points (S2).

264 STAT1 had a similar pattern of modulation to SOCS1 with both the IM-A and BI-A groups
265 showing increases, while in Phase B, only the IM-B group had significant fold increases (Fig.
266 3). However, the same positive individuals exhibiting elevated fold increases of SOCS1 also
267 had high fold increases of STAT1 (S1 and S2).

268

269 *Cellular response*

270 The regulation of CD40, CD8 α , CD4-1, MHCII β , NF κ B, IL-2R β , IL-2 and IL-15 genes was
271 measured in an effort to evaluate cellular immune responses during the experiment. The level
272 of the costimulatory molecule CD40 mRNA was up-regulated in both the IM and BI groups in
273 Phase A and B. The highest fold change in the IM-A and BI-A groups, corresponding to a 2-
274 fold up-regulation compared to the control group, and was observed at 21 dpi. Interestingly, at
275 21 dpi, two negative individuals in the IM-A group showed more than a 7-fold increase when
276 the median value in the IM-A group was 2-fold. Approximately 2-fold increases were apparent
277 in the IM-B and BI-B groups at 14 dpi, one week earlier than groups in Phase A (Fig. 4). CD40
278 mRNA levels in the IM-A, BI-A and IM-B groups reached a peak at 21 dpi and the BI-B group
279 showed only a moderate increase during the course of the experiment. SAV-positive fish had
280 a higher average value of CD40 mRNA abundance than SAV-negative fish in the IM-A and
281 IM-B groups at 7 and 3 dpi, respectively.

282 The T cell co-receptors, CD4-1 and CD8 α , were relatively unchanged showing a slight down-
283 regulation in all groups (Fig. 4). CD4-1 transcript abundance in Phase A was slightly
284 downregulated at 7 dpi, but by 28 dpi it had increased 2-3-fold in all groups. A different CD4-
285 1 transcription pattern was observed in infected groups in Phase B where the basal mRNA level
286 was lower than in Phase A and unchanged throughout the sampling period. (Fig. 4). In the IM-
287 B group at 3 dpi, three SAV-positive individuals showed more than a 4-fold increase, while in
288 the BI-B group two negative individuals showed 2- and 4-fold increases, when the median
289 value in both groups was 1-fold (S2 and Fig 4).

290 Differences in median values of the CD8 α transcript levels between infected groups and control
291 groups in Phase A and B were small, but there was a slight downward regulation in Phase A.
292 Whereas in Phase B transcripts were stable throughout the sampling period (Fig. 4).
293 Interestingly, some of the individuals from the IM-A and BI-A groups, which had high
294 transcript levels of CD8 α at 21 and 28 dpi, also showed elevated levels of CD40 and CD4-1.

295 The MHCII β gene regulation pattern was different in Phase A and B for both infected groups
296 compared to their respective controls (Fig. 5). MHCII β was relatively unchanged in Phase A.
297 The IM-B group showed a significant increase in MHCII β mRNA levels at 14 and 21 dpi,
298 corresponding to a doubling compared to the control group, followed by a decrease at 28 dpi.
299 Moreover, the basal mRNA levels of the MHCII β was higher in the CT-B group than in the
300 CT-A group significantly so at 14 dpi (S3).

301 NF κ B mRNA abundance was slightly up-regulated in both infected groups in Phase A whereas
302 in Phase B transcript levels were stable. In Phase A, the median value of each group at all time-
303 points was mostly higher than in Phase B, when the IM-A group was elevated over 2-fold at
304 21 and 28 dpi. In Phase B, both infected groups were highest at 14 dpi but decreased to control
305 values at 28 dpi (Fig. 5).

306 The IL-2R β gene encodes a cytokine receptor protein that interacts specifically with IL-2. IL-
307 2R β transcript levels were rapidly up-regulated after SAV3 infection, as indicated by the
308 detection of elevated levels in both infected groups in both phases at 3 dpi (Fig. 5). These
309 changes in transcript levels were accompanied by changes in the control groups resulting in
310 significantly lower fold changes in the BI-A group at 28 dpi, when both the IM-A and CT-A
311 groups showed over 2-fold increases.

312 The members of the IL-2 subfamily of cytokines, namely IL-2 and IL-15, was also analysed
313 (Fig. 6). IL-2 mRNA level was regulated to only a small extent in both phases, while IL-15
314 mRNA abundance was unchanged in Phase A, except a 2-fold increase at 14 dpi in the IM-B
315 group. Interestingly, the lower expression of IL-2 mRNA in the BI-A group at 28 dpi was
316 reflected in the lower expression of its receptor, IL-2R β , at the same time-point.

317

318 *Humoral response*

319 Both IgM and IgT mRNA levels were up-regulated during the experiment, but a week later in
320 Phase A compared to Phase B (Fig. 7). In Phase A, both infected groups exhibited the similar
321 median value of IgM and IgT mRNA abundance and both were upregulated at 21 and 28 dpi.
322 In the IM-B group, IgM and IgT transcript levels reached a peak at 14 and 21 dpi respectively,
323 and a trend of down-regulation at 28 dpi could be seen. IgM mRNA was only up-regulated in
324 SAV-positive fish in the BI-B group and 5 of 7 positive individuals showed ≥ 4 -fold (4, 4, 4, 5,
325 9) increase at 28 dpi (S2). Moreover, IgT transcript levels in the BI-B group were also higher
326 in SAV-positive fish relative to SAV-negative fish at 21 and 28 dpi, and such differences were
327 statistically significant (S2).

328

329 **3.3 Differences between control fish in both phases**

330 We found differences in the basal transcript level in some of the analysed genes between the
331 CT-A and CT-B groups (Table 2 and S3). CD40, CD4-1, CD8 α , and SOCS1 were more
332 abundantly regulated in the CT-A than in the CT-B, and the differences were significantly
333 higher at 3 and 28 dpi (Table 2 and S3). The basal transcript level of NF κ B, IL-15, and RIG-1
334 were also significantly higher in the CT-A group, but only at 28 dpi. In contrast, other genes
335 showed a higher expression in the CT-B group compared to the CT-A group, as seen with the
336 MHCII β at 14 dpi, IgM at 7 and 14 dpi, and the IL-18 with a peak at 7 dpi.

337

338 **3.4 Neutralizing antibody titres**

339 Plasma and serum samples collected at 21 and 28 dpi were assayed for the presence of SAV-
340 neutralizing antibodies. In Phase A, the fish had no detectable neutralizing antibodies neither
341 at 21 nor at 28 dpi.

342 Neutralizing antibodies were not detected in the plasma samples from the control fish nor in
343 those from any of the infected groups at 21 dpi in Phase B. At 28 dpi 67% (12 of 18) of the

344 IM-B group and 11% (2 of 18) of the BI-B group plasma samples had neutralizing antibodies
345 at detectable titres. All individuals showing an antibody response were positive for SAV RNA
346 and in the BI-B group both SAV-positive fish with neutralizing antibodies had titres of $\geq 1:40$
347 (Fig. 8). Similarly, in the serum samples, 17% (3 of 18) of the IM-B group at 21 dpi, 77% (14
348 of 18) of the IM-B group at 28 dpi and 22% (4 of 18) of the BI-B group at 28 dpi had
349 neutralizing antibodies (Table 3).

350

351 **4. Discussion**

352 The salmon farming industry suffers huge economic losses due to PD outbreaks every year.
353 Despite the use of vaccines against SAV by some of the farms, PD is still regularly observed
354 during the grow-out phase in seawater. Although several studies have examined immune
355 responses to SAV in Atlantic salmon, most of the mechanisms leading to protection still remain
356 unclear. Therefore, the identification of measures that can potentially prevent or at least reduce
357 SAV infection after seawater transfer is of particular interest. Thus, in this study, we have used
358 our recently described BI challenge model to examine the relative regulation of genes involved
359 in innate and adaptive responses to virus infection [23,19]. Taken together with previous
360 studies from our laboratory, the results described here give a more detailed understanding of
361 the differences in the anti-viral immune responses that develop in fish from the same
362 production batch that are infected with SAV at either 2 or 9 weeks after seawater transfer.

363 RIG-1 is a pattern recognition receptor (PRR) that interacts with dsRNA leading to the
364 production of type I interferons (IFNs) and the expression of IFN-stimulated genes (ISGs) [29].

365 RIG-1 showed similar patterns of transcription as another PRR, LGP2a, in Phase A and B
366 [19,23]. Both PRRs were highly up-regulated in both phases and the up-regulation in phase A
367 was greater. Moreover, RIG-1 was one of the most highly constitutively expressed immune
368 gene examined in this study.

369 IL-10 is a member of the class II cytokine family that inhibits the activity of Th1 cells, natural
370 killer cells, and macrophages. It has been demonstrated that it plays an important role in both
371 the earliest and later anti-inflammatory responses to SAV3 infection [16]. In this study, we
372 analysed the regulation of IL-10 gene until 4 wpi and up-regulation at 7 dpi in the IM-A group
373 and at 14 dpi in the BI-A, IM-B, and BI-B groups could be observed. Whereas, the pro-
374 inflammatory fish cytokine, IL-18, which induces IFN- γ production and promotes Th1
375 immunity in vertebrates [30] was relatively unchanged in both phases during the whole
376 experiment.

377 STAT1 and SOCS1 are an activator and an inhibitor of the JAK/STAT signaling pathway,
378 respectively, furthermore, both are crucially involved in the control of inflammatory responses.
379 Both genes showed a high level of mRNAs at 7 dpi in all infected groups and had similar
380 profiles of expression in Phase A and B, suggesting that they are regulating each other. The
381 upregulation in the BI-A group, although lower, was maintained for a longer time compared to
382 the IM-A group. This pattern of expression was similar to that which was observed for a
383 number of other innate immune genes in this group of fish after SAV infection [23]. The high
384 transcript abundance of SOCS1 has been suggested to be a consequence of SAV infection and
385 may be a survival strategy for the virus. Increasing SOCS1 mRNA expression may
386 subsequently inhibit signal transduction via the JAK/STAT pathway and may contribute to
387 viral replication [31,32]. In our previous study, we observed a reduction in ISG and Mx
388 expression in the IM-B group [19] that partially may be due to up-regulation of the SOCS1
389 after SAV infection.

390 Regulation of IL-10, RIG-1, SOCS1, and STAT-1 genes in Phase A for both challenge models
391 (represented by trend-lines on the figures) was consistent with our previous results on the innate
392 immune genes associated with the IFN response or with inflammation [23]. Expression of these
393 transcripts was higher in head kidney samples from Phase A relative to Phase B, which

394 suggested a greater inflammatory response in Phase A. Interestingly, an abundance of
395 inflammatory cells was observed as early as 7 dpi in SAV3 target-organs (pancreas and heart)
396 in Phase B post-smolts, indicating activation of a cellular immune response to SAV3, which
397 was not observed in Phase A fish [18]. Furthermore, the regulation of the genes mentioned
398 above, and also of IgT and CD40, was delayed by one week in the BI-A fish when compared
399 to the IM-A fish. This suggests that, in the BI group, the immune response to SAV3 was
400 delayed in comparison to the IM infection, probably due to the infection route and/or the
401 reduced viral dose.

402 Most of the adaptive immune genes studied here did not change significantly during the
403 experimental period. However, the accumulative effect of many small changes in the transcript
404 level of several genes in the same signaling pathway may produce biological effects. This is
405 illustrated by the slight up-regulation in both IM-A and CT-A at 28 dpi in several genes all
406 involved in cellular immunity; CD40, CD4-1, CD8 α , IL-2, IL2R β and IL-15 when the BI-A
407 group showed no change at this time-point. Furthermore, IgT and IgM mRNA transcript levels
408 were seen to be higher in fish that also showed a high expression of CD40, CD4-1 and CD8 α
409 mRNA.

410 Also, of these genes the T-cell co-receptors genes, CD4-1 and CD8 α , were not significantly
411 up-regulated during this study at any time-point in any of the groups, suggesting that the T cell
412 response was not induced in response to SAV3 infection, at least in the first 4 weeks after
413 infection. This is consistent with previous results showing that up-regulation of CD4-1 and
414 CD8 α was not detected at the earlier time points in co-habitation trials. However, both genes
415 were found to be significantly expressed at 6 and 8 weeks post-infection [33,16,17]. On the
416 other hand, we detected high mRNA levels of MHCII β , CD40, and IL-15 in head kidney
417 samples from the IM-B group, which are indicative of activation of a more cell-mediated
418 immune response. MHCII β is a part of the MHCII complex, which is involved in antigen

419 presentation and is normally expressed on antigen-presenting cells. Its expression was
420 significantly up-regulated at 14 and 21 dpi in the IM-B group, in contrast to previous studies
421 where regulation of MHCII mRNAs was only detected after 8 weeks in target organs during
422 SAV3 co-habitation infection [16,33]. A similar observation of later/delayed response of
423 MHCII expression was reported after infection with ISAV [34]. In addition, the costimulatory
424 molecule CD40, a transmembrane glycoprotein, which is a member of the tumor necrosis factor
425 (TNF) receptor superfamily and plays an immune-regulatory function in the adaptive response
426 [35], was studied. CD40 was up-regulated at 7 dpi in both, the IM-A and IM-B groups, and this
427 up-regulation was maintained for a longer time in the IM-B group. Furthermore, the cytokine
428 IL-15, which is induced by IFN- γ in salmon leucocytes and plays a role in promoting Th1
429 responses and memory T cell maturation, was significantly up-regulated in the IM-B group at
430 14 dpi [36]. We also observed that IgM and IgT were highly up-regulated in the IM-B group.
431 Previously our lab has shown that higher numbers of IgM⁺ and MHC II⁺ cells could be detected
432 by immune-histo-chemical staining of the heart and pancreas of IM-B fish [37]. Taken together
433 with findings presented here, this suggests that a larger population of B cells was present in the
434 head kidney in the IM-B group.

435 Increased regulation of IgM and IgT genes was especially interesting since we were able to
436 link gene expression data with the presence or absence of SAV neutralizing antibodies in
437 individual fish. A neutralizing antibody response was clearly detected in Phase B, where only
438 moderate increases (3-4-fold) in gene expression levels led to high titres of neutralizing
439 antibodies. The plasma results show a lack of a neutralizing antibody response after only 2
440 weeks in seawater compared to the Phase B fish. Besides, many plasma samples from Phase A
441 fish displayed a toxic reaction to the CHSE-214 cell line used in the neutralization assay, which
442 was not seen with any of the Phase B samples. In addition, the serum results from Phase B fish
443 support the high titres observed in plasma samples and appear more sensitive with both

444 detectable antibodies at 21 dpi and more SAV3-positive individuals. Three of the 4 BI-B fish
445 with detectable neutralizing antibodies were also shown to be SAV-positive and had a high
446 abundance of IgM mRNA (3.9-, 4- and 4.7-fold change). The results from the BI-B group are
447 more difficult to interpret due to the lower dose of virus present in the shedder water and the
448 lower prevalence of SAV positive fish detected in this group. Interestingly, very little
449 pancreatic pathology was observed in two of these fish, perhaps indicating that the immune
450 response, especially the antibody response had successfully cleared the virus. The apparent
451 lack of an antibody response in Phase A may be explained by the ability of the SAV nsP2
452 protein to suppress the host antiviral response and shut-off protein expression [38-40]. This
453 ability may be one of the factors that contribute to the poor immune response seen during SAV
454 infection in Phase A, despite the elevated abundance of several genes in fish recently
455 transferred to seawater. Thus, we can speculate that although the basal expression of some of
456 the genes studied was found to be greater in CT-A than in CT-B, fish from Phase B were able
457 to mount a more effective response that could have inhibited the SAV mediated host-shut-off
458 protein mechanism. Conversely, many innate immune genes were more highly expressed in
459 Phase B [19], but it is quite possible that the timely production of neutralizing antibodies is
460 decisive in mitigating SAV3 infection since previous studies have shown antibodies to both
461 neutralize SAV and protect against infection [41]. On the other hand, inflammatory cells and
462 MHC class II+ and IgM+ cells were observed in a greater number in the target organs in the
463 CT-B group [16,37].

464

465 In conclusion, Atlantic salmon post-smolts transferred to seawater at the same time, and
466 challenged at week 2 and 9, 7 weeks apart, displayed very different immune responses
467 following infection with SAV3. Fish adapted to seawater for an extra 7 weeks appeared to have
468 a better developed and more effective cell-mediated and humoral response against SAV3

469 infection, resulting in only mild histopathological changes in the pancreas and heart, and a
470 reduced susceptibility to SAV3 infection.

471

472 **Conflict of interest**

473 The authors declare no conflict of interest.

474

475 Funding

476 This research was funded by the Research Council of Norway [grant number 224885/E40].

477

478 **Abbreviations**

479 BI bath immersion

480 cDNA complementary DNA

481 Dpi Days post infection

482 IFN interferon

483 IL Interleukin

484 IM Intramuscular injection

485 ISGs interferon-stimulated genes

486 MHCII β Major Histocompatibility Complex class II beta chain

487 NF κ B Nuclear factor kappa-light-chain-enhancer of activated B

488 RIG-1 Retinoic-acid-inducible protein 1

489 RT-qPCR reverse transcriptase quantitative polymerase chain reaction

490 SOCS1 Suppressor of cytokine signaling 1

491 SWT seawater transfer

492 TCID₅₀ 50% tissue culture infective dose

493 TCR T cell receptor

494 wpt weeks post seawater transfer

495

496 **Acknowledgements**

497 Øystein Evensen, Norwegian University of Life Sciences, is acknowledged for providing the
498 SAV3 isolate. The following people are thanked for their expert technical assistance and help
499 during sampling and analysis; Stig Mæhle and Ingrid U. Fiksdal. Thanks also to Ivar Helge
500 Matre (Matre Research Station, Institute for Marine Research) for production of fish and
501 Joachim Nordbø for fish husbandry and help with sampling.

502

503

504 **Highlights**

- 505 • Neutralizing abs to SAV were detected only in salmon adapted for longer to seawater.
- 506 • Salmon adapted for longer to SW develop stronger cell-mediated immunity to SAV.
- 507 • Upon shorter adaptation to SW, salmon show IL-10 upregulation at early time points.
- 508 • SOCS1 gene was upregulated in all infected groups in both phases.
- 509 • Upon shorter adaptation to SW, SOCS1 upregulation was maintained for longer time.

510

511 **5. References**

512 [1] M.F. McLoughlin, R.N. Nelson, J.I. McCormick, H.M. Rowley, D.B. Bryson, Clinical and
513 histopathological features of naturally occurring pancreas disease in farmed Atlantic salmon,
514 *Salmo salar* L., *J. Fish. Dis.* 25(1) (2002) 33-43.

515 [2] E. Fringuelli, H.M. Rowley, J.C. Wilson, R. Hunter, H. Rodger, D.A. Graham, Phylogenetic
516 analyses and molecular epidemiology of European salmonid alphaviruses (SAV) based on
517 partial E2 and nsP3 gene nucleotide sequences, *J. Fish. Dis.* 31(11) (2008) 811–823.

518 [3] M.D. Jansen, B. Bang Jensen, M.F. McLoughlin, H.D. Rodger, T. Taksdal, H. Sindre, D.A.
519 Graham, A. Lillehaug, The epidemiology of pancreas disease in salmonid aquaculture: a
520 summary of the current state of knowledge, *J. Fish. Dis.* 40(1) (2017) 141-155.

- 521 [4] M.J. Hjortaa, B. Bang Jensen, T. Taksdal, A.B. Olsen, A. Lillehaug, E. Trettenes, H.
522 Sindre, Genetic characterization of salmonid alphavirus in Norway, *J. Fish. Dis.* 39(2) (2016)
523 249-257.
- 524 [5] B. Hjeltne, G. Bornø, M.D. Jansen, A. Haukaas, C. Walde, (Eds.), *The Health Situation in*
525 *Norwegian Aquaculture 2016*, Norwegian Veterinary Institute (2017).
- 526 [6] A. Bergheim, S. Fivelstad, Atlantic salmon (*Salmo salar* L.) in aquaculture: metabolic rate
527 and water flow requirements in T.K. Woo Patrick, J. Noakes Donald (Eds.), *Salmon: Biology,*
528 *Ecological Impacts and Economic Importance*, Nova Science Publishers, Inc., University of
529 Guelph Guelph, Ontario, Canada and others, 2014, pp. 155-172.
- 530 [7] M.F. McLoughlin, D.A. Graham, Alphavirus infections in salmonids—a review, *J. Fish.*
531 *Dis.* 30(9) (2007) 511–531.
- 532 [8] S.D. McCormick, T.F. Sheehan, B.T. Björnsson, C. Lipsky, J.F. Kocik, A.M. Regish, M.F.
533 O'Dea, Physiological and endocrine changes in Atlantic salmon smolts during hatchery rearing,
534 downstream migration, and ocean entry, *Can. J. Fish Aquat. Sci.* 70(1) (2013) 105-118.
- 535 [9] L.H. Johansson, G. Timmerhaus, S. Afanasyev, S.M. Jørgensen, A. Krasnov, Smoltification
536 and seawater transfer of Atlantic salmon (*Salmo salar* L.) is associated with systemic repression
537 of the immune transcriptome, *Fish. Shell. Imm.* 58 (2016) 33-41.
- 538 [10] E.F. Pettersen, M. Ulvenes, G.O. Melingen, H.I. Wergeland, Peripheral blood and head
539 kidney leucocyte populations during out-of-season (0+) parr-smolt transformation and
540 seawater transfer of Atlantic salmon (*Salmo salar* L.), *Fish. Shell. Imm.*, 15(5) (2003) 373-385.
- 541 [11] G.O. Melingen, S.O. Stefansson, A. Berg, H.I. Wergeland, Changes in serum protein and
542 IgM concentration during smolting and early post-smolt period in vaccinated and unvaccinated
543 Atlantic salmon (*Salmo salar* L.), *Fish. Shell. Imm.* 5(3) (1995) 211-221.

- 544 [12] M. Muona, A. Soivio, Changes in plasma lysozyme and blood leucocyte levels of
545 hatchery-reared Atlantic salmon (*Salmo salar* L.) and sea trout (*Salmo trutta* L.) during
546 parresmolt transformation, *Aquaculture* 106(1) (1992) 75-87.
- 547 [13] K.A. Glover, C. Skår, K.E. Christie, J. Glette, H. Rudra, Ø. Skaala, Size-dependent
548 susceptibility to infectious salmon anemia virus (ISAV) in Atlantic salmon (*Salmo salar* L.) of
549 farm, hybrid and wild parentage, *Aquaculture* 254(1-4) (2006) 82-91.
- 550 [14] Z. Heidari, J. Tinsley, R. Bickerdike, M.F. McLoughlin, J. Zou, S. A. Martin, Antiviral
551 and metabolic gene expression responses to viral infection in Atlantic salmon (*Salmo salar*),
552 *Fish. Shell. Imm.* 42(2) (2015) 297-305.
- 553 [15] T.K. Herath, J.E. Bron, K.D. Thompson, J.B. Taggart, A. Adams, J.H. Ireland, R.H.
554 Richards, Transcriptomic analysis of the host response to early stage salmonid alphavirus
555 (SAV-1) infection in Atlantic salmon *Salmo salar* L. *Fish. Shell. Imm.* 32(5) (2012) 796-807.
- 556 [16] C. Xu, T.C. Guo, S. Mutoloki, Ø. Haugland, Ø. Evensen, Gene expression studies of host
557 response to salmonid alphavirus subtype 3 experimental infections in Atlantic salmon, *Vet.*
558 *Res.* 43(1) (2012) 78.
- 559 [17] S. Grove, L. Austbø, K. Hodneland, P. Frost, M. Løvoll, M. McLoughlin, H.L. Thim, S.
560 Braaen, M. König, M. Syed, J.B. Jørgensen, E. Rimstad, Immune parameters correlating with
561 reduced susceptibility to pancreas disease in experimentally challenged Atlantic salmon
562 (*Salmo salar*), *Fish. Shell. Imm.* 34(3) (2013) 789-798.
- 563 [18] J. Jarungsriapisit, L.J. Moore, G.L. Taranger, T.O. Nilsen, H.C. Morton, I.U. Fiksdal,
564 S. Stefansson, P.G. Fjellidal, Ø. Evensen, S. Patel, Atlantic salmon (*Salmo salar* L.) post-smolts
565 challenged two or nine weeks after seawater-transfer show differences in their susceptibility to
566 salmonid alphavirus subtype 3 (SAV3). *Virolog. J.* 13(1) (2016) 66.
- 567 [19] L.J. Moore, J. Jarungsriapisit, T.O. Nilsen, S. Stefansson, G.L. Taranger, C.J. Secombes,
568 H.C. Morton, S. Patel, Atlantic salmon adapted to seawater for 9 weeks develop a robust

569 immune response to salmonid alphavirus upon bath challenge. *Fish. Shell. Imm.* 74 (2018)
570 573-583.

571 [20] C. Xu, T.C. Guo, S. Mutoloki, Ø. Haugland, I.S. Marjara, Ø. Evensen, Alpha interferon
572 and not gamma interferon inhibits salmonid alphavirus subtype 3 replication in vitro. *J. Virol.*
573 84(17) (2010) 8903–8912.

574 [21] L.J. Reed, H. Muench, A simple method of estimating fifty per cent endpoints, *Am. J.*
575 *Epidemiol.* 27(3) (1938) 493–497.

576 [22] A.J.A. McBeath, M. Snow, C.J. Secombes, A.E. Ellis, B. Collet, Expression kinetics of
577 interferon and interferon-induced genes in Atlantic salmon (*Salmo salar*) following infection
578 with infectious pancreatic necrosis virus and infectious salmon anaemia virus. *Fish. Shell.*
579 *Imm.* 22(3) (2007) 230–241.

580 [23] L.J. Moore, J. Jarungsriapisit, T.O. Nilsen, S. Stefansson, G.L. Taranger, C.J. Secombes,
581 C. J., H.C. Morton, S. Patel, Immune gene profiles in Atlantic salmon (*Salmo salar* L.) post-
582 smolts infected with SAV3 by bath-challenge show a delayed response and lower levels of
583 gene transcription compared to injected fish, *Fish. Shell. Imm.* 62 (2017) 320-331.

584 [24] Ø. Kileng, V. Bergan, S.T. Workenhe, B. Robertsen, Structural and functional studies of
585 an IRF-7-like gene from Atlantic salmon, *Dev. Comp. Immunol.* 33(1) (2009) 18-27.

586 [25] T.M. Tadisio, A. Krasnov, S. Skugor, S. Afanasyev, I. Hordvik, F. Nilsen, Gene expression
587 analyses of immune responses in Atlantic salmon during early stages of infection by salmon
588 louse (*Lepeophtheirus salmonis*) revealed bi-phasic responses coinciding with the copepod-
589 chalimus transition, *BMC genomics* 12(1) (2011) 141.

590 [26] P.A. Olsvik, K.K. Lie, A.E.O. Jordal, T.O. Nilsen, I. Hordvik, Evaluation of potential
591 reference genes in real-time RT-PCR studies of Atlantic salmon, *BMC Molecular Biology* 6(1)
592 (2005) 1-9.

593 [27] M. Løvoll, L. Austbø, J.B. Jørgensen, E. Rimstad, P. Frost, Transcription of reference
594 genes used for quantitative RT-PCR in Atlantic salmon is affected by viral infection, *Vet. Res.*
595 42(1) (2011) 8.

596 [28] D.A. Graham, V.A. Jewhurst, H.M. Rowley, M.F. McLoughlin, D. Todd, A rapid
597 immunoperoxidase-based virus neutralisation assay for salmonid alphaviruses used for
598 serological survey in Northern Ireland, *J. Fish. Dis.* 26(7) (2003) 407-413.

599 [29] M. Chang, B. Collet, P. Nie, K. Lester, S. Campbell, C.J. Secombes, J. Zou, Expression
600 and functional characterization of the RIG-I like receptors MDA5 and LGP2 in rainbow trout
601 *Oncorhynchus mykiss*. *J. Virol.* (2011) JVI-00445.

602 [30] J. Zou, C.J. Secombes, The function of fish cytokines. *Biology* 5(2) (2016) 23.

603 [31] M. Sobhkhez, L.L. Joensen, L.G. Tollersrud, G. Strandskog, H.L. Thim, J.B. Jørgensen,
604 A conserved inhibitory role of suppressor of cytokine signaling 1 (SOCS1) in salmon antiviral
605 immunity, *Dev. Comp. Immunol.* 67 (2017) 66-76.

606 [32] C. Xu, Ø. Evensen, H.M. Munang'andu, A de novo transcriptome analysis shows that
607 modulation of the JAK-STAT signaling pathway by salmonid alphavirus subtype 3 favors virus
608 replication in macrophage/dendritic-like TO-cells, *BMC genomics* 17(1) (2016) 390.

609 [33] L.H. Johansen, H.L. Thim, S.M. Jørgensen, S. Afanasyev, G. Strandskog, T. Taksdal, K.
610 Fremmerlid, M. McLoughlin, J.B. Jørgensen, A. Krasnov, Comparison of transcriptomic
611 responses to pancreas disease (PD) and heart and skeletal muscle inflammation (HSMI) in heart
612 of Atlantic salmon (*Salmo salar* L.), *Fish. Shell. Imm.* 46(2) (2015) 612-623.

613 [34] S.M. Jørgensen, D.L. Hetland, C.M. Press, U. Grimholt, T. Gjøen, Effect of early
614 infectious salmon anaemia virus (ISAV) infection on expression of MHC pathway genes and
615 type I and II interferon in Atlantic salmon (*Salmo salar* L.) tissues, *Fish. Shell. Imm.* 23(3)
616 (2007) 576-588.

- 617 [35] L.X. Lagos, D.B. Iliev, R. Helland, M. Roseblatt, J.B. Jørgensen, CD40L—a
618 costimulatory molecule involved in the maturation of antigen presenting cells in Atlantic
619 salmon (*Salmo salar*), *Dev. Comp. Immunol.* 38(3) (2012) 416-430.
- 620 [36] T. Wang, J.W. Holland, A. Carrington, J. Zou, C.J. Secombes, Molecular and functional
621 characterisation of interleukin-15 in rainbow trout *Oncorhynchus mykiss*: A potent inducer of
622 interferon-gamma expression in spleen leucocytes, *J. Immunol.* 179(3) (2007) 1475–1488.
- 623 [37] J. Jarungsriapisit, L.J. Moore, I.U. Fiksdal, H. Bjørgen, A. Tangerås, B. Köllner, E.O.
624 Koppang, S. Patel, Time after seawater transfer influences immune cell abundance and
625 responses to SAV3 infection in Atlantic salmon, *J. Fish Dis.* (2018) 1–14.
- 626 [38] J.J. Fros, G.P. Pijlman, Alphavirus infection: host cell shut-off and inhibition of antiviral
627 responses, *Viruses* 8(6) (2016) 166.
- 628 [39] N. Bhalla, C. Sun, L.M. Lam, C.L. Gardner, K.D. Ryman, W. B. Klimstra, Host translation
629 shutoff mediated by non-structural protein 2 is a critical factor in the antiviral state resistance
630 of Venezuelan equine encephalitis virus, *Virology* 496 (2016) 147-165.
- 631 [40] J.C. Rupp, K.J. Sokoloski, N.N. Gebhart, R.W. Hardy, Alphavirus RNA synthesis and
632 non-structural protein functions, *J. Gen. Virol.* 96(9) (2015) 2483-2500.
- 633 [41] G. Houghton, A.E. Ellis, Pancreas disease in Atlantic salmon: serum neutralisation and
634 passive immunization, *Fish. Shell. Imm.* 6(6) (1996) 465-472.

635

636 **Figure legends**

637 **Fig. 1. Experimental setup and percentage prevalence of SAV-positive hearts.**

638 **A.** Atlantic salmon post- smolts 2 weeks (Phase A) or 9 weeks (Phase B) post seawater-transfer
639 (wpt) were infected with SAV3. Treatments performed in triplicate tanks consisted of
640 intramuscular (*i.m.*) injection with non-infected cell culture supernatant (CT group), with 10^4
641 TCID₅₀ SAV3 (IM group), and bath challenge in water containing shed virus (BI group).

642 Shedder fish were *i.m.* injected with SAV3 approx. 1 week before the day of experimental
643 challenge. 8 fish per tank (24 fish per treatment group) were collected at each sampling time-
644 point: 3, 7, 14, 21 and 28 days post-infection (dpi). **B.** Bars represent mean percentage of
645 SAV3-RNA positive samples \pm SEM at each time point of the IM-A (black bars), IM-B (dark
646 grey bars), BI-A (white bars) and BI-B (light grey bars) groups. N=24 for all groups and time-
647 points (except for the BI-A group at 14 dpi where n=22 and the IM-B group at 7 and 28 dpi
648 where n = 22 and 23 respectively).

649

650 **Fig. 2. Fold change in mRNA levels of IL-18 and IL-10.**

651 The y axis represents normalized, fold changes in mRNA levels for each treatment group
652 compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles
653 for each group with the median value shown by a black bar within each box. The whiskers
654 represent the maximum and minimum values for each group. Open bars represent the CT
655 group, dark grey bars the IM group and light grey bars the BI group. The left panels correspond
656 to the Phase A and the right panels correspond to the Phase B groups. Trend lines indicate
657 transcriptional changes over time; solid line IM group and dashed line the BI group. Asterisks
658 denote statistically significant differences between the infected and CT groups: * $p < 0.05$, **
659 $p < 0.01$ and *** $p < 0.001$. Lower case letters indicate statistically significant differences
660 between the IM and BI groups: ^a $p < 0.05$, ^b $p < 0.01$ and ^c $p < 0.001$.

661

662 **Fig. 3. Fold change in mRNA levels of RIG-1, SOCS1, and STAT1.**

663 The y axis represents normalized, fold changes in mRNA levels for each treatment group
664 compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles
665 for each group with the median value shown by a black bar within each box. The whiskers
666 represent the maximum and minimum values for each group. Open bars represent the CT

667 group, dark grey bars the IM group and light grey bars the BI group. The left panels correspond
668 to the Phase A and the right panels correspond to the Phase B groups. Trend lines indicate
669 transcriptional changes over time; solid line IM group and dashed line the BI group. Asterisks
670 denote statistically significant differences between the infected and CT groups: * $p < 0.05$, **
671 $p < 0.01$ and *** $p < 0.001$. Lower case letters indicate statistically significant differences
672 between the IM and BI groups: ^a $p < 0.05$, ^b $p < 0.01$ and ^c $p < 0.001$.

673

674 **Fig. 4. Fold change in mRNA levels of CD40, CD4-1, and CD8 α .**

675 The y axis represents normalized, fold changes in mRNA levels for each treatment group
676 compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles
677 for each group with the median value shown by a black bar within each box. The whiskers
678 represent the maximum and minimum values for each group. Open bars represent the CT
679 group, dark grey bars the IM group and light grey bars the BI group The left panels correspond
680 to the Phase A and the right panels correspond to the Phase B groups. Trend lines indicate
681 transcriptional changes over time; solid line IM group and dashed line the BI group. Asterisks
682 denote statistically significant differences between the infected and CT groups: * $p < 0.05$, **
683 $p < 0.01$ and *** $p < 0.001$. Lower case letters indicate statistically significant differences
684 between the IM and BI groups: ^a $p < 0.05$, ^b $p < 0.01$ and ^c $p < 0.001$.

685

686 **Fig. 5. Fold change in mRNA levels of MHCII β , NF κ B, and IL-2R β .**

687 The y axis represents normalized, fold changes in mRNA levels for each treatment group
688 compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles
689 for each group with the median value shown by a black bar within each box. The whiskers
690 represent the maximum and minimum values for each group. Open bars represent the CT
691 group, dark grey bars the IM group and light grey bars the BI group. The left panels correspond

692 to the Phase A and the right panels correspond to the Phase B groups. Trend lines indicate
693 transcriptional changes over time; solid line IM group and dashed line the BI group. Asterisks
694 denote statistically significant differences between the infected and CT groups: * $p < 0.05$, **
695 $p < 0.01$ and *** $p < 0.001$. Lower case letters indicate statistically significant differences
696 between the IM and BI groups: ^a $p < 0.05$, ^b $p < 0.01$ and ^c $p < 0.001$.

697

698 **Fig. 6. Fold change in mRNA levels of IL-2 and IL-15.**

699 The y axis represents normalized, foldchanges in mRNA levels for each treatment group
700 compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles
701 for each group with the median value shown by a black bar within each box. The whiskers
702 represent the maximum and minimum values for each group. Open bars represent the CT
703 group, dark grey bars the IM group and light grey bars the BI group. The left panels correspond
704 to the Phase A and the right panels correspond to the Phase B groups. Trend lines indicate
705 transcriptional changes over time; solid line IM group and dashed line the BI group. Asterisks
706 denote statistically significant differences between the infected and CT groups: * $p < 0.05$, **
707 $p < 0.01$ and *** $p < 0.001$. Lower case letters indicate statistically significant differences
708 between the IM and BI groups: ^a $p < 0.05$, ^b $p < 0.01$ and ^c $p < 0.001$.

709

710 **Fig. 7. Fold changes in mRNA levels of IgM and IgT.**

711 The y axis represents normalized, fold changes in mRNA levels for each treatment group
712 compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles
713 for each group with the median value shown by a black bar within each box. The whiskers
714 represent the maximum and minimum values for each group. Open bars represent the CT
715 group, dark grey bars the IM group and light grey bars the BI group. The left panels correspond
716 to the Phase A and the right panels correspond to the Phase B groups. Trend lines indicate

717 transcriptional changes over time; solid line IM group and dashed line the BI group. Asterisks
718 denote statistically significant differences between the infected and CT groups: * $p < 0.05$, **
719 $p < 0.01$ and *** $p < 0.001$. Lower case letters indicate statistically significant differences
720 between the IM and BI groups: ^a $p < 0.05$, ^b $p < 0.01$ and ^c $p < 0.001$.

721

722 **Fig. 8. Neutralizing antibody titres to SAV at 28 dpi in fish from Phase B groups.**

723 Percentage of fish producing neutralizing antibodies to SAV in plasma samples at 28 dpi. Grey
724 bars represent the *i.m.* injected group (IM-B) and black bars represent the bath challenged
725 group (BI-B).

726

727 **Table 1. Primer sequences.** Primers employed in this study, product size, relative efficiencies
728 and the Genbank accession numbers used for primer design or the reference for previously
729 published assays.

730

731 **Table 2. Significant differences (ANOVA on log transformed data followed by Tukey's**
732 **multiple comparisons test) in gene expression at all time-points and for all genes**
733 **comparing Phase A to Phase B.** * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$.

734

735 **Table 3. Neutralizing antibody titres.** Number of fish with neutralizing antibodies in plasma
736 and serum samples in fish from Phase B groups.

737

738 **S1. Immune gene mRNA levels in control, positive and negative fish for SAV3-RNA in**
739 **Phase A.** Graphs show trend lines between average fold change \pm SEM positive IM-A (light
740 blue) and BI-A (yellow) and negative IM-A (dark blue), BI-A (red) and CT-A (black) groups
741 for all genes analysed.

742

743 **S2. Immune gene mRNA levels in control, positive and negative fish for SAV3-RNA in**

744 **Phase B.** Graphs show trend lines between average fold change \pm SEM positive IM-A (light
745 blue) and BI-A (yellow) and negative IM-A (dark blue), BI-A (red) and CT-A (black) groups
746 for all genes analysed.

747

748 **S3. Fold changes in mRNA levels between control fish in both phases.**

749 The y axis represents normalized, fold changes in mRNA levels for each treatment group
750 compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles
751 for each group with the median value shown by a black bar within each box. The whiskers
752 represent the maximum and minimum values for each group. Dark grey bars represent the CT-
753 A group and light grey bars the CT-B group. Trend lines indicate transcriptional changes over
754 time; solid line CT-A group and dashed line the CT-B group. Asterisks denote significant
755 differences between the CT groups: * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$.

756

757 Table 1

Gene	Primers sequences	Efficiency	Product size bps*	References/Genbank accession No.
CD40	Fwd: GCCCTGCCAAGAGGATGA Rv: GTCAGGCACTCTTTACTGGAACA	2,06	173	NM_0011412361
STAT1	Fwd: TGTCTGTTGGCTCAGTTGCG Rv: GAAATTGATGCTGTGGCGTCT	1,92	100	[24] / NM_001123654.1
SOCS1	Fwd: CATTCCGCTGCCAAGTAGAC Rv: CCGTGGCGACGTCCTT	1,95	127	KF699315
MHCIIβ	Fwd: CTCCTGAGCCCATGGTGTAT Rv: GAGTCCTGCCAAGGCTAAGATG	1,90	117	[25] / BT060311
EF1A	Fwd: CCCCTCCAGGACGTTTACAAA Rv: CACACGGCCACAGGTACA	2,02	57	[26] / BG936182.1
CD8α	Fwd: CTTCAGCGAGGAGCAGATAAAC Rv: GGCTGTGGTCATTGGTGTAGTC	2,04	187	NM_001123583.1
CD4-1	Fwd: GTGGAGGTGCTACAGGTGTTTTTC Rv: GGGGAGGAGCCTAAAGCG	2,00	158	EU409794.1
RIG-1	Fwd: CCTCTGCTACAGGAGCCAATA Rv: GCCGTTGGTGCACAGAT	1,95	157	NM_001163699.1
NFκB	Fwd: GCACTACCATTTTACTGACGCA Rv: GCGTTGGGTGACTTGCTGT	2,07	188	NM_001173583.1
IL-18	Fwd: GAGCAATGCAAAGCAGATGATT Rv: GCTCCAGTGGTTTGGCAGAA	2,07	177	BT125392.1
IL-15	Fwd: GCTTCTTAATATTGAGCTGCCTGA Rv: GGCATCTGATTTTTCTATGGTACTT	2,04	146	NM_001279065.1
IL-2	Fwd: GCGGATGTAGAGAAAAGCATTG Rv: CATTCTGACGAGTCCGTTCTGAT	2,32	155	HE805272.1
IL-10	Fwd: GCTATGGACAGCATCCTGAAGTT Rv: GGTGTTCTGCGTTCTGTTGTT	1,99	76	EF165028
IL-2Rβ	Fwd: CTCCAAGGACTGTTTTGTGTGAA Rv: GAGGTGCTCGGCTGAACTGA	1,95	242	NM_001140548.1
IgM	Fwd: CCAGTGAAGAAACAAGCGGAAT Rv: CCTCATCCATTTGATTGTGTGTGTA	2,02	157	S48652
IgT	Fwd: CAACAAAGTCACTGTCACCTGGAA Rv: CCGTCAGCGTTCTGTTTTG	2,10	212	GQ907003.1

758 *bps = base pairs

759

Table 2

Gene Assay	Treatment	3 dpi			7 dpi			14 dpi			21 dpi			28 dpi		
		CT-B	IM-B	BI-B	CT-B	IM-B	BI-B	CT-B	IM-B	BI-B	CT-B	IM-B	BI-B	CT-B	IM-B	BI-B
CD40	CT-A	*	*	**					***					*		
	IM-A				*				*					*		
	BI-A												**			
CD4-1	CT-A	***	*	**										***	***	***
	IM-A	**		*							*	*	*	***	***	***
	BI-A	*						*	*	**	**	***	***	***	***	***
CD8 α	CT-A	**	*	*										***	**	**
	IM-A	*												***		*
	BI-A															
MHCI β	CT-A					**	*	***	***	***		***				*
	IM-A				*	***	**	**	***	**		***			*	**
	BI-A					*		**	***	**		***			*	**
NF κ β	CT-A													**	*	*
	IM-A	*										*	**	**	*	*
	BI-A				*		*	**				*	**			*
IL-2R β	CT-A															*
	IM-A															
	BI-A															
IgM	CT-A				**	***	***	**	***	**		***				
	IM-A				*	***	**		***	***	**	***		***		
	BI-A					***	**		***	**	**		***		**	
IgT	CT-A					**			***							
	IM-A										***	**	***			
	BI-A					**					***		***			
IL-2	CT-A															*
	IM-A															
	BI-A															
IL-10	CT-A								***	**						
	IM-A				***	***	***	*						***	*	**
	BI-A							***			***	**	***	*		
IL-15	CT-A								***					***	*	**
	IM-A								***					*		
	BI-A								*							
IL-18	CT-A				*				***							
	IM-A				***	**	**		***							
	BI-A				**				***							
RIG-1	CT-A					**	*		***			**		***	***	***
	IM-A				***	***	***	***		***	**	***	***	***	***	***
	BI-A				**			***		***	***	***	***	***	***	***
SOCS1	CT-A	*	***	***					***					***	***	***
	IM-A		*	**	***	**	***	***	*	***	**	***		***	***	**
	BI-A			*	***		**	***	***	***	***	***	***	***	***	***
STAT1	CT-A					***			***							
	IM-A				***		*									
	BI-A						*	*			***	***	***			

Table 3

Group	Sample	Titre				Total
		1:20	1:30	1:40	<1:40	
IM-B 21 dpi	Plasma					0
	Sera	2	1			3
BI-B 21 dpi	Plasma					0
	Sera					0
IM-B 28 dpi	Plasma	2	3	3	4	12
	Sera	2	4	3	5	14
BI-B 28 dpi	Plasma			1	1	2
	Sera		3		1	4

Fig. 1





Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7






Fig. 8



S1


Positive and negative fish Phase A



S1. Immune gene mRNA levels in control, positive and negative fish for SAV3-RNA in Phase A. Graphs show trend lines between average fold change \pm SEM positive IM-A (light blue) and BI-A (yellow) and negative IM-A (dark blue), BI-A (red) and CT-A (black) groups for all genes analysed.

S2

Positive and negative fish Phase B



S2. Immune gene mRNA levels in control, positive and negative fish for SAV3-RNA in Phase B. Graphs show trend lines between average fold change \pm SEM positive IM-A (light blue) and BI-A (yellow) and negative IM-A (dark blue), BI-A (red) and CT-A (black) groups for all genes analysed.

S3

Fold Changes

